Skip to main content

Day: November 28, 2023

Spectroscopy Announces the Acquisition of Spectroscopy Europe and Spectroscopy World

Ian Michael was the Editor and Publisher of Spectroscopy Europe and Spectroscopy World since 1975, where he wrote about the latest trends in analytical sciences.Michael cared very deeply about the advertisers and readers of both publications, and always added a personal touch to his work.CRANBURY, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) — MJH Life Sciences® and Spectroscopy® are thrilled to announce the acquisition of Spectroscopy Europe and Spectroscopy World, two leading digital magazines for experts in the analytical sciences. This acquisition will expand Spectroscopy’s global reach, growing its audience to more than 71,500 readers worldwide. The merger of the publications will expand Spectroscopy’s mission to provide valuable, practical and leading-edge information to the spectroscopy community. “This exciting...

Continue reading

Inventronics Announces 2023 Q3 Financial Results

CALGARY, Alberta, Nov. 28, 2023 (GLOBE NEWSWIRE) — Inventronics Limited (“Inventronics” or the “Corporation”) (IVX:TSX Venture), a designer and manufacturer of enclosures for the telecommunications, cable, power distribution, energy and other industries in North America, today announced its unaudited 2023 Q3 financial results. For the three months ended September 30, 2023, Inventronics reported a net loss of $94,000, or 1.9 cents per share, on revenue of $1,463,000 compared to net earnings of $536,000, or 11.1 cents per share, on revenue of $3,400,000 for the three months ended September 30, 2022. For the nine months ended September 30, 2023, Inventronics reported net earnings of $576,000, or 11.8 cents per share, on revenue of $7,900,000 compared to net earnings of $1,841,000, or 38.3 cents per share, on revenue of $11,374,000...

Continue reading

CPS Technologies Corporation to Participate in Virtual Investor Summit on December 7, 2023

NORTON, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) — CPS Technologies Corporation (NASDAQ:CPSH) (“CPS” or the “Company”) today announced that it will participate in the Virtual Investor Summit conference, open to institutional investors, on December 7. A general presentation, to be webcast live, will be held at 10:00 am Eastern.  Event: Investor Summit  Presentation: December 7th, 2023 @ 10:00 AM ET  Location: https://us06web.zoom.us/webinar/register/WN_TYPCYNyXTJKHkcMtrzLfkwFor one-on-one investor calls, please contact the Investor Summit Group directly or CPS Technologies investor relations. About CPS CPS is a technology and manufacturing leader in producing high-performance energy management components that facilitate the electrification of the economy. Our products and intellectual property include critical pieces of...

Continue reading

Prosper Gold Corp. Closes Second Tranche of Private Placement and Prepares for Winter Drilling at Golden Sidewalk Project

VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) — Prosper Gold Corp. (“Prosper Gold” or the “Company“) (TSXV:PGX) announces that it has mobilized a crew to the Golden Sidewalk Project (the “Project”) in northwest Ontario in preparation for winter diamond drilling. The Company further announces it has closed the second tranche (the “Second Tranche”) of the previously announced non-brokered private placement financing (the “Financing”) (i) of units (each, a “Unit”) and (ii) common shares of the Company that qualify as “flow through shares” for purposes of the Income Tax Act (Canada) (“FT Shares”). A crew has been mobilized to the Golden Sidewalk Project in the Red Lake Mining District, Northwest Ontario, to lay out drill pads and access roads. Up to 2,500 metres will be drilled at three previously...

Continue reading

Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit

EDISON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that it will present at the 7th Obesity & NASH Drug Development Summit taking place November 27 – 29, 2023 in Boston. Scott Campbell, PhD, Hepion’s Quantitative Translational Pharmacologist, will deliver an oral presentation on the use of AI / machine learning (“ML”) to enrich NASH clinical trials and for NASH patient selection; and the use of multi-omics with ML for biomarker response prediction. Presentation details:Title: Using AI/ML and Multi-Omics to...

Continue reading

Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update

Product revenue for the nine months of 2023 increased to $29.8 million, compared to $11.1 million for the same period in 2022Marketing authorization was received for AVT04 in Canada and Japan, the first for a biosimilar to Stelara® (ustekinumab)The European Medicines Agency proposed market authorization for AVT04 in the 30 member states of the European Economic Area, pending a final decision by the European CommissionApprovability of AVT02 and AVT04 in the U.S. now pending satisfactory US Food and Drug Administration (FDA) inspection of Alvotech’s facility in Iceland, currently expected on January 10 – 19, 2024Management will conduct a business update conference call and live webcast on Wednesday November 29, 2023, at 8:00 am ET (13:00 pm GMT)REYKJAVIK, Iceland, Nov. 28, 2023 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO,...

Continue reading

Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update

Product revenue for the nine months of 2023 increased to $29.8 million, compared to $11.1 million for the same period in 2022 Marketing authorization was received for AVT04 in Canada and Japan, the first for a biosimilar to Stelara® (ustekinumab) The European Medicines Agency proposed market authorization for AVT04 in the 30 member states of the European Economic Area, pending a final decision by the European Commission Approvability of AVT02 and AVT04 in the U.S. now pending satisfactory US Food and Drug Administration (FDA) inspection of Alvotech’s facility in Iceland, currently expected on January 10 – 19, 2024 Management will conduct a business update conference call and live webcast on Thursday November 29, 2023, at 8:00 am ET (13:00 pm GMT)Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the...

Continue reading

Kane Biotech Announces Improved Third Quarter 2023 Financial Results

29% Increase in Product and Services Revenue; 26% Increase in Total Revenue WINNIPEG, Manitoba, Nov. 28, 2023 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its third quarter 2023 financial results. Third Quarter Financial Highlights:Revenue from product and services for the three months ended September 30, 2023 was $548,785 an increase of 29% from $425,671 in the three months ended September 30, 2022. This increase is due mainly to higher STEM Animal Health (STEM) online and pet retail sales in the current period. Royalty and license revenue for the three months ended September 30, 2023 was $169,067, an increase of 16% compared to $146,015 in the three months ended September 30, 2022. This increase is due mainly to incremental license revenue in the current period...

Continue reading

Leslie’s, Inc. Announces Fourth Quarter & Fiscal 2023 Financial Results; Provides Fiscal 2024 Outlook

Sales of $432.4 million in the fourth quarter and $1,451.2 million in Fiscal 2023 Net income of $16.5 million in the fourth quarter and $27.2 million in Fiscal 2023 Adjusted EBITDA of $59.5 million in the fourth quarter and $168.1 million in Fiscal 2023 Diluted earnings per share of $0.09 in the fourth quarter and $0.15 in Fiscal 2023 Adjusted diluted earnings per share of $0.14 in the fourth quarter and $0.28 in Fiscal 2023PHOENIX, Nov. 28, 2023 (GLOBE NEWSWIRE) — Leslie’s, Inc. (“Leslie’s”, “we”, “our” or “its”; NASDAQ: LESL), the largest and most trusted direct-to-consumer brand in the U.S. pool and spa care industry, today announced its financial results for the fourth quarter and Fiscal 2023. Mike Egeck, Chief Executive Officer said, “Following three years of unprecedented growth, the pool industry and Leslie’s faced multiple...

Continue reading

RGC Resources, Inc. Raises Annual Dividend to $0.80 per Share

ROANOKE, Va., Nov. 28, 2023 (GLOBE NEWSWIRE) — The Board of Directors of RGC Resources, Inc. (NASDAQ: RGCO), at its meeting on November 27, 2023, declared a quarterly dividend of $0.20 per share on the Company’s common stock. The indicated annual dividend is $0.80 per share, a $0.01 or 1.3% per share increase over the prior annual level. The Company has now increased the annual dividend 20 consecutive years. Paul Nester, CEO of RGC Resources, Inc., stated, “The Roanoke Gas utility continues to deliver solid operational and financial performance. Further, we look forward to seeing the MVP completed in 2024. This dividend increase, our 20th annual increase, reflects our commitment to deliver long-term shareholder value.” The dividend will be paid on February 1, 2024 to shareholders of record on January 17, 2024. This is the Company’s...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.